Page last updated: 2024-12-07

2-pyrazinoylguanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-pyrazinoylguanidine: inhibits secretion of urea by kidney tubules [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124704
CHEMBL ID1911974
CHEMBL ID1962516
SCHEMBL ID565773
MeSH IDM0157506

Synonyms (22)

Synonym
2-pyrazinoylguanidine
n-(diaminomethylidene)pyrazine-2-carboxamide
60398-24-5
AKOS005257145
unii-g15v730jcm
g15v730jcm ,
pyrazinecarboxamide, n-(aminoiminomethyl)-
CHEMBL1911974 ,
bdbm50356112
SCHEMBL565773
n-(pyrazine-2-carbonyl)-guanidine
CHEMBL1962516
pyrazinoylguanidine
2-pyrazinecarboxamide, n-(aminoiminomethyl)-
DTXSID40209151
(diaminomethylene) pyrazine carboxamide
n-carbamimidoylpyrazine-2-carboxamide
SB74409
n-(aminoiminomethyl)-2-pyrazinecarboxamide
CS-0454097
EN300-7816245
mfcd00898033
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.56)18.7374
1990's16 (88.89)18.2507
2000's1 (5.56)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (27.78%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]